Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: A 5-year review

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 4, 2014, Pages 428-433

  Banerji, Aleena ^a   Lax, Timothy ^a   Guyer, Autumn ^a   Hurwitz, Shelley ^a   Camargo, Carlos A ^a   Long, Aidan A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Allergy; Desensitization; Drug hypersensitivity

Indexed keywords

CARBOPLATIN; PACLITAXEL; ALLERGEN;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ARTICLE; BACKACHE; CANCER INCIDENCE; CHEST TIGHTNESS; CHILL; COMMON COLD; CONTROLLED STUDY; COUGHING; CYANOSIS; DESENSITIZATION; DIZZINESS; DYSPNEA; ERYTHEMA; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; ONCOLOGY; OUTPATIENT CARE; PREMEDICATION; RETROSPECTIVE STUDY; RIGOR; SYMPTOMATOLOGY; TACHYCARDIA; THORAX PAIN; THROAT TIGHTNESS; URTICARIA; VOMITING; AMBULATORY CARE; BACK PAIN; CANCER CENTER; COMPARATIVE STUDY; DRUG HYPERSENSITIVITY; IMMUNOLOGY; INFUSION PUMP; PROCEDURES; PRURITUS;

ADULT; AGED; ALLERGENS; AMBULATORY CARE; BACK PAIN; CARBOPLATIN; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFUSION PUMPS; MALE; MIDDLE AGED; ONCOLOGY SERVICE, HOSPITAL; PACLITAXEL; PRURITUS; RETROSPECTIVE STUDIES;

EID: 84904056922     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.04.010     Document Type: Article

References (25)

1. Global Cancer Facts and Figures2008 2008, American Cancer Society, American Cancer Society, Atlanta, GA.
2. Facts and Figures 2004, American Cancer Society, American Cancer Society, Atlanta, GA.
3. Hunn J., Rodriguez G.C. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012, 55:3-23.
4. Zanotti K.M., Rybicki L.A., Kennedy A.W., Belinson J.L., Webster K.D., Kulp B., et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. JClin Oncol 2001, 19:3126-3129.
5. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. JClin Oncol 2000, 18:102-105.
6. Brown S.G. Clinical features and severity grading of anaphylaxis. JAllergy Clin Immunol 2004, 114:371-376.
7. Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 2009, 29:585-606.
8. Hesterberg P.E., Banerji A., Oren E., Penson R.T., Krasner C.N., Seiden M.V., et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. JAllergy Clin Immunol 2009, 123:1262-1267.e1.
9. Polyzos A., Tsavaris N., Kosmas C., Arnaouti T., Kalahanis N., Tsigris C., et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001, 61:129-133.
10. Patil S.U., Long A.A., Ling M., Wilson M.T., Hesterberg P., Wong J.T., et al. Aprotocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. JAllergy Clin Immunol 2012, 129:443-447.
11. Lenz H.J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007, 12:601-609.
12. Peereboom D.M., Donehower R.C., Eisenhauer E.A., McGuire W.P., Onetto N., Hubbard J.L., et al. Successful re-treatment with Taxol after major hypersensitivity reactions. JClin Oncol 1993, 11:885-890.
13. Zanotti K.M., Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001, 24:767-779.
14. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006, 7:1041-1053.
15. Sampson H.A., Muñoz-Furlong A., Campbell R.L., Adkinson N.F., Bock S.A., Branum A., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. JAllergy Clin Immunol 2006, 117:391-397.
16. Lieberman P., Nicklas R.A., Oppenheimer J., Kemp S.F., Lang D.M., Bernstein D.I., et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. JAllergy Clin Immunol 2010, 126:477-480.e1-42.
17. Castells M.C., Tennant N.M., Sloane D.E., Hsu F.I., Barrett N.A., Hong D.I., et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. JAllergy Clin Immunol 2008, 122:574-580.
18. Castells M. Rapid desensitization of hypersensitivity reactions to chemotherapy agents. Curr Drug Saf 2006, 1:243-251.
19. Lee C.W., Matulonis U.A., Castells M.C. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004, 95:370-376.
20. Madrigal-Burgaleta R., Berges-Gimeno M.P., Angel-Pereira D., Ferreiro-Monteagudo R., Guillen-Ponce C., Pueyo C., et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013, 68:853-861.
21. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 2012, 23(Suppl 10):x313-x319.
22. Laskin M.S., Lucchesi K.J., Morgan M. Paclitaxel rechallenge failure after a major hypersensitivity reaction. JClin Oncol 1993, 11:2456-2457.
23. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). NEngl J Med 1995, 332:1004-1014.
24. Kloover J.S., den Bakker M.A., Gelderblom H., van Meerbeeck J.P. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004, 90:304-305.
25. Afatal anaphylactic reaction to paclitaxel is described, which was preceded byapossible delayed reaction to the initial infusion. Allergy Asthma Proc 2011, 32:79.